Search

everythinglearnresearchcommunity

for

Search:↓

The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.

The mTOR signaling pathway might play a role in radiation dermatitis, but more research is needed.

Activin increases skin tumor formation, skin Tregs help hair growth, lymph-node removal doesn't improve melanoma survival, cells can revert to stem cells in wound healing, and skin bacteria produce peptides that may treat infections.

K10 may not prevent tumors as previously thought and might increase benign tumor risk.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.

Cancer survivors often experience worse skin problems from treatment than expected, and working with dermatologists could help improve their condition.

Fixing DNA errors is crucial to prevent skin cancer.

Radiation therapy with chemotherapy can cause severe, long-lasting hair loss.

Chemotherapy causes complex changes in hair follicle cells that can lead to hair loss.

HPV infection is linked to better survival in advanced anal cancer, higher radiation doses improve survival, especially in HPV-negative patients, and prostaglandin E₂ pretreatment can protect mouse hair follicles from radiation damage.

A new gene mutation linked to Olmsted syndrome may increase cancer risk, suggesting the need for ongoing patient monitoring.

New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.

Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.

Targeted cancer therapies often cause serious skin problems that need careful management.

ODC overexpression in hair cells increases tumor growth by reducing Notch signaling.

Different types of skin gland tumors have unique genetic traits, which can guide personalized treatments.

Trichilemmal carcinoma shares genetic traits with other skin cancers, suggesting similar treatment options.

Improving treatment plans can reduce hair loss and improve life quality for ovarian cancer patients.

Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.

VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Trichilemmal carcinoma shares genetic changes with other skin cancers, suggesting similar causes and potential treatments.

Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.

The research shows that skin cancer likely originates from hair follicles and that certain cell populations expand to promote skin cancer growth.

Topoisomerase inhibitors can cause hair loss, skin rash, hand-foot syndrome, and nail changes.

Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.